<DOC>
	<DOCNO>NCT00876122</DOCNO>
	<brief_summary>This open-label , Phase I , dose-escalation study use 3 + 3 design ass safety , tolerability , pharmacokinetics orally administer GDC-0941 administer QD . This study include patient locally advance metastatic solid tumor , NHL , multiple myeloma ( MM ) ( expansion stage ) standard therapy either exist proven ineffective intolerable .</brief_summary>
	<brief_title>A Study GDC-0941 Patients With Locally Advanced Metastatic Solid Tumors Non-Hodgkin 's Lymphoma Which Standard Therapy Either Does Not Exist Has Proven Ineffective Intolerable</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Histologically cytologically document , incurable , locally advanced metastatic solid malignancy NHL without leukemic phase progress failed respond least one prior regimen Multiple myeloma ( MM ) patient ( Stage 2 ) : document pathologic diagnosis MM relapse failed respond treatment least one prior systemic therapy ( corticosteroid monotherapy ) Evaluable measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) per International Working Group ( IWG ) response criterion NonHodgkin 's lymphoma ( NHL ) patient Life expectancy &gt; = 12 week Documented willingness use effective mean contraception men woman participate study For patient participate Stage 1 adequate exposure predict observed basis PK analysis approximately 12 patient participate Stage 2 ( exclude patient MM ) : A biopsyaccessible lesion tissue obtain safely CT guidance direct visualization agreement patient undergo sequential ( pretreatment posttreatment ) biopsy . For patient participate Stage 2 DCEMRI MRS imaging : Patients least one metastatic liver lesion measure &gt; = 5 cm one dimension one tumor lesion elsewhere measure &gt; = 2 cm one dimension ( lung mediastinum lesion qualify ) basis CT scan Leptomeningeal disease manifestation current malignancy History Type 1 2 diabetes mellitus require regular medication Any condition require anticoagulant , warfarin , heparin , thrombolytic Inability unwillingness swallow pill Malabsorption syndrome condition would interfere enteral absorption Known untreated CNS malignancy treat brain metastasis radiographically stable &gt; = 3 month Congenital long QT syndrome QTc &gt; 500 msec , determine least two three baseline ECG measurement Active congestive heart failure ventricular arrhythmia require medication Uncontrolled ascites require weekly large volume paracentesis 3 consecutive week prior enrollment Active infection require intravenous ( IV ) antibiotic Patients require daily supplemental oxygen DLco , 50 % predict value correct AV Hgb prior initiation study treatment Uncontrolled hypomagnesemia hypokalemia , define value low limit normal ( LLN ) hypercalcemia ULN institution despite adequate electrolyte supplementation management Clinically significant history liver disease , include viral hepatitis , current alcohol abuse , cirrhosis Known human immunodeficiency virus ( HIV ) infection Any disease , active uncontrolled pulmonary dysfunction , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug may affect interpretation result render patient high risk treatment complication Significant traumatic injury within 3 week Day 1 Major surgical procedure within 4 week prior initiation study treatment Prior allogeneic hematopoietic stem cell transplantation ( HSCT ) time autologous HSCT within 12 week study entry Treatment chemotherapy , hormonal therapy ( except GnRH agonists antagonist prostate cancer ) , immunotherapy , biologic therapy , radiation therapy ( except palliative radiation bony metastasis ) cancer therapy within 4 week prior initiation study treatment ( exception kinase inhibitor approve local regulatory authority , may use within 2 week prior initiation study treatment , provide drugrelated toxicity completely resolve approval Medical Monitor grant ) Palliative radiation bony metastasis within 2 week prior initiation study treatment Need chronic corticosteroid therapy Treatment investigational agent within 4 week prior initiation study treatment Unresolved toxicity prior therapy , except alopecia Grade 1 peripheral neuropathy Pregnancy lactation Inability comply study followup procedure For patient eligible participate Stage 2 DCEMRI MRS assessment , contraindication MRI examination , include follow : Imbedded metallic material/devices ( metal implant large tattoos field view ) Severe claustrophobia Physical characteristic ( weight size ) exceed capability MRI scanner Known allergy hypersensitivity reaction gadolinium , verse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>NHL</keyword>
	<keyword>Metastatic Solid Tumors</keyword>
	<keyword>PI3K Inhibitors</keyword>
	<keyword>PI3K</keyword>
</DOC>